Added to YB: 2026-09-14
Pitch date: 2026-09-11
IMRX [bullish]
Immuneering Corporation
Author Info
No bio for this author
Company Info
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.
Market Cap
$298.3M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.92
P/E
-4.71
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Day 3 Session 3 - Immuneering Corporation
IMRX (quick overview): Immuneering’s next-generation MEK inhibitor has a compelling but unvalidated first-line pancreatic-cancer story: its Phase 2 combination with gemcitabine/nab-paclitaxel delivered 17.3 months median overall survival, ~60% second-line treatment access and weight stability or gain at three months in ~84% of evaluable patients. The central question is whether these results survive Phase 3 randomization and a larger population; AACR pancreatic-cancer data are expected in late September, while the Phase 3 readout is targeted for 2028.
Read full article (2 min)